Effect of Renal and Hepatic Impairment on the Pharmacokinetics of Pritelivir and Its Metabolites

Ähnliche Einträge

• Mass Balance and Metabolite Profile after Single and Multiple Oral Doses of Pritelivir in Healthy Subjects
  von: Susanne Bonsmann, et al.
  Veröffentlicht: (2024)
• Evaluation of the Clinical Drug‐Drug Interaction Potential of Pritelivir on Transporters and CYP450 Enzymes Using a Cocktail Approach
  von: Michiel de Vries, et al.
  Veröffentlicht: (2024)
• Effect of Hepatic and Renal Impairment on the Pharmacokinetics of Dersimelagon (MT‐7117), an Oral Melanocortin‐1 Receptor Agonist
  von: Akihito Ogasawara, et al.
  Veröffentlicht: (2024)
• Effect of Renal Impairment on the Pharmacokinetics and Safety of Doxecitine and Doxribtimine: A Single‐Dose Phase 1 Study
  von: Aravind Mittur, et al.
  Veröffentlicht: (2026)
• A Phase 1, Open‐Label, Single‐Dose Study of the Effect of Hepatic Impairment on the Pharmacokinetics of Erdafitinib, an FGFR Inhibitor
  von: Wei Zhu, et al.
  Veröffentlicht: (2026)